Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04965831 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2021 | clinicaltrials |
| NCT02824965 | Pembrolizumab + CVA21 in Advanced NSCLC | unknown | Phase 1 | 11 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04951648 | A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation | unknown | Phase 3 | 220 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04952168 | Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC | unknown | Phase 2 | 26 | Yuan ChenOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04950400 | A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC | unknown | N/A | 60 | Beijing Chest HospitalOTHER | 0 | Jul 6, 2021 | clinicaltrials |
| NCT04942301 | PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy | unknown | Phase 1 | 24 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04945200 | Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer | unknown | — | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT04944069 | Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis(ATTRACT) | unknown | N/A | 69 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT04941417 | Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients | unknown | Phase 2 | 60 | Peking Union Medical CollegeOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT01711697 | An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 16 | Emory UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04541251 | Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC | unknown | Phase 2 | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04932343 | Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor | unknown | — | 20 | Samsung Medical CenterOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT03447678 | Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.(PEOPLE) | unknown | Phase 2 | 65 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04919616 | An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC) | unknown | Early Phase 1 | 15 | Shanghai OriginCell Therapeutics Co., Ltd.INDUSTRY | 0 | Jun 9, 2021 | clinicaltrials |
| NCT04905550 | Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC | unknown | Phase 2 | 50 | Chongqing University Cancer HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT04828395 | Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer(F&C) | unknown | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT04874844 | JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety | unknown | Phase 2 / Phase 3 | 420 | Beijing Dongfang Biotech Co., Ltd.INDUSTRY | 0 | May 10, 2021 | clinicaltrials |
| NCT04878692 | Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies(OPERA) | unknown | N/A | 96 | Hospices Civils de LyonOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04304248 | Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer(NeoTAP01) | unknown | Phase 2 | 30 | Hao LongOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | unknown | Phase 1 | 192 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04865705 | Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer | unknown | Phase 2 | 33 | West China HospitalOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04857970 | Routine Electronic Monitoring Of Quality Of Life -Poumon (REMOQOL-Poumon) | unknown | — | 72 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT04840290 | A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC | unknown | Phase 3 | 30 | Tang-Du HospitalOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT04825925 | Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments | unknown | N/A | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 12, 2021 | clinicaltrials |
| NCT04725448 | Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma | unknown | Phase 2 | 27 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826913 | High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization(TUMOVASC) | unknown | — | 100 | University Hospital, Strasbourg, FranceOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03878537 | Recurrence Monitoring in NSCLC Using Circulating Tumor DNA | unknown | — | 50 | Scripps Translational Science InstituteOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03373955 | A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients | unknown | — | 60 | Sichuan UniversityOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT02667743 | Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC | unknown | Phase 3 | 454 | Shanghai Yizhong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04722406 | Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy. | unknown | — | 350 | Sun Yat-sen UniversityOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04797806 | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC(SAINT) | unknown | Phase 3 | 206 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04793139 | Efficacy and Safety of Camrelizumab in Real-World Prospective Study | unknown | — | 1,000 | Guangdong Association of Clinical TrialsOTHER | 0 | Mar 11, 2021 | clinicaltrials |
| NCT04292119 | Lorlatinib Combinations in Lung Cancer | unknown | Phase 1 / Phase 2 | 96 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02927340 | A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions | unknown | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00643318 | CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer | unknown | Phase 2 | 40 | Accuray IncorporatedINDUSTRY | 2 | Mar 5, 2021 | clinicaltrials |
| NCT03976856 | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | unknown | Phase 1 | 42 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04137588 | Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | unknown | — | 126 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT04629027 | Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC | unknown | — | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT04768491 | Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC | unknown | — | 82 | Peking Union Medical CollegeOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT03986528 | Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 4 | 334 | Jie LiOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04761640 | The Impact of Polynuclear Neutrophils' Intra-tumoral Rate and the Mutational Status in Pulmonary Adenocarcinomas on Survival | unknown | — | 100 | Central Hospital, Nancy, FranceOTHER | 0 | Feb 21, 2021 | clinicaltrials |
| NCT04762030 | Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study | unknown | Phase 2 | 39 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04753918 | Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study | unknown | Early Phase 1 | 3 | Taoyuan General HospitalOTHER_GOV | 0 | Feb 15, 2021 | clinicaltrials |
| NCT04749407 | Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer | unknown | — | 50 | First People's Hospital of HangzhouOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04741633 | Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy(NSCLC) | unknown | — | 25 | Fudan UniversityOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT02500199 | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | unknown | Phase 1 | 50 | Hengrui Therapeutics, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2021source: clinicaltrials